未经治疗的乳腺癌的肿瘤承载降低了大鼠的运动耐量,但不降低最大摄氧量。

IF 3.6 3区 医学 Q2 ONCOLOGY
American journal of cancer research Pub Date : 2025-02-15 eCollection Date: 2025-01-01 DOI:10.62347/QCCZ2316
Ramona E Weber, Kiana M Schulze, Nathan J Kenney, Britton C Scheuermann, Olivia N Kunkel, Carl J Ade, Timothy I Musch, Brad J Behnke, David C Poole
{"title":"未经治疗的乳腺癌的肿瘤承载降低了大鼠的运动耐量,但不降低最大摄氧量。","authors":"Ramona E Weber, Kiana M Schulze, Nathan J Kenney, Britton C Scheuermann, Olivia N Kunkel, Carl J Ade, Timothy I Musch, Brad J Behnke, David C Poole","doi":"10.62347/QCCZ2316","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer patients' maximal O<sub>2</sub> uptake (V̇O<sub>2</sub>max) values average 60-80% of age-predicted values which is often attributed to adjuvant therapy rather than risk factors, comorbidities, or the tumor and associated factors (e.g., pro-inflammatory cytokines). It is crucial to understand the physiological mechanisms behind exercise intolerance in breast cancer patients to enhance targeted interventions; however, the effect of breast cancer, as an isolated condition on V̇O<sub>2</sub>max, exercise tolerance, and resting cardiac function has not been investigated. We hypothesized that breast cancer, in the absence of underlying conditions or chemotherapy, would lower V̇O<sub>2</sub>max, exercise tolerance, and cardiac function in proportion to tumor mass. Female Fischer-344 rats (~6-8 months, n = 8) were acclimatized to treadmill running for 5 days at 25 m/min for 5 min/day. To measure V̇O<sub>2</sub>max, rats were placed within a plexiglass metabolic chamber connected to CO<sub>2</sub> and O<sub>2</sub> analyzers. Tests began at 25 m/min and increased (5 m/min) until exhaustion. Cardiac function was determined by echocardiography before rats received a mammary intraductal injection of rat adenocarcinoma cells (MATBIII, 6 × 10<sup>3</sup> in 50 µl saline). Tumor growth was monitored daily and ~7 days following palpation (~24 days post-injection), V̇O<sub>2</sub>max and echocardiography measurements were repeated. Tumor mass and volume were 2.1 ± 0.6 g and 1685 ± 428 (range 256-3749) mm<sup>3</sup>, respectively. Body mass (217 ± 6 vs 218 ± 6 g), V̇O<sub>2</sub>max (72.1 ± 2.7 vs 70.0 ± 2.8 ml/kg·min; P > 0.05), and all measures of cardiac function were unchanged following tumor formation, with no significant correlation between tumor mass and V̇O<sub>2</sub>max (P > 0.05). However, time to exhaustion (376 ± 20 vs 297 ± 25 s), final treadmill speed (48 ± 1 vs 42 ± 2 m/s), distance run (209 ± 16 vs 152 ± 18 m), and total work (45 ± 3 vs 32 ± 4 m·kg) were significantly reduced with tumor bearing. Contrary to our hypothesis, breast cancer did not affect V̇O<sub>2</sub>max or cardiac function, but reduced exercise tolerance.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 2","pages":"487-500"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897639/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tumor bearing in untreated breast cancer decreases exercise tolerance without lowering maximal oxygen uptake in rats.\",\"authors\":\"Ramona E Weber, Kiana M Schulze, Nathan J Kenney, Britton C Scheuermann, Olivia N Kunkel, Carl J Ade, Timothy I Musch, Brad J Behnke, David C Poole\",\"doi\":\"10.62347/QCCZ2316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Breast cancer patients' maximal O<sub>2</sub> uptake (V̇O<sub>2</sub>max) values average 60-80% of age-predicted values which is often attributed to adjuvant therapy rather than risk factors, comorbidities, or the tumor and associated factors (e.g., pro-inflammatory cytokines). It is crucial to understand the physiological mechanisms behind exercise intolerance in breast cancer patients to enhance targeted interventions; however, the effect of breast cancer, as an isolated condition on V̇O<sub>2</sub>max, exercise tolerance, and resting cardiac function has not been investigated. We hypothesized that breast cancer, in the absence of underlying conditions or chemotherapy, would lower V̇O<sub>2</sub>max, exercise tolerance, and cardiac function in proportion to tumor mass. Female Fischer-344 rats (~6-8 months, n = 8) were acclimatized to treadmill running for 5 days at 25 m/min for 5 min/day. To measure V̇O<sub>2</sub>max, rats were placed within a plexiglass metabolic chamber connected to CO<sub>2</sub> and O<sub>2</sub> analyzers. Tests began at 25 m/min and increased (5 m/min) until exhaustion. Cardiac function was determined by echocardiography before rats received a mammary intraductal injection of rat adenocarcinoma cells (MATBIII, 6 × 10<sup>3</sup> in 50 µl saline). Tumor growth was monitored daily and ~7 days following palpation (~24 days post-injection), V̇O<sub>2</sub>max and echocardiography measurements were repeated. Tumor mass and volume were 2.1 ± 0.6 g and 1685 ± 428 (range 256-3749) mm<sup>3</sup>, respectively. Body mass (217 ± 6 vs 218 ± 6 g), V̇O<sub>2</sub>max (72.1 ± 2.7 vs 70.0 ± 2.8 ml/kg·min; P > 0.05), and all measures of cardiac function were unchanged following tumor formation, with no significant correlation between tumor mass and V̇O<sub>2</sub>max (P > 0.05). However, time to exhaustion (376 ± 20 vs 297 ± 25 s), final treadmill speed (48 ± 1 vs 42 ± 2 m/s), distance run (209 ± 16 vs 152 ± 18 m), and total work (45 ± 3 vs 32 ± 4 m·kg) were significantly reduced with tumor bearing. Contrary to our hypothesis, breast cancer did not affect V̇O<sub>2</sub>max or cardiac function, but reduced exercise tolerance.</p>\",\"PeriodicalId\":7437,\"journal\":{\"name\":\"American journal of cancer research\",\"volume\":\"15 2\",\"pages\":\"487-500\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897639/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/QCCZ2316\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/QCCZ2316","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

乳腺癌患者的最大氧摄取(V * O2max)值平均为年龄预测值的60-80%,这通常归因于辅助治疗,而不是危险因素、合并症或肿瘤及其相关因素(如促炎细胞因子)。了解乳腺癌患者运动不耐受背后的生理机制对加强有针对性的干预至关重要;然而,作为一种孤立的疾病,乳腺癌对vo2max、运动耐量和静息心功能的影响尚未得到研究。我们假设,在没有基础疾病或化疗的情况下,乳腺癌患者的vo2max、运动耐量和心功能与肿瘤质量成正比。雌性fisher -344大鼠(~6-8个月,n = 8)适应在跑步机上以25 m/min的速度跑步5天,每天5分钟。为了测量v_o2max,将大鼠置于连接CO2和O2分析仪的有机玻璃代谢室中。试验以25米/分钟的速度开始,然后增加到5米/分钟,直到精疲力竭。在大鼠接受乳腺导管内注射大鼠腺癌细胞(MATBIII, 6 × 103, 50µl生理盐水)之前,通过超声心动图检测心功能。每日及触诊后~7天(注射后~24天)监测肿瘤生长情况,重复测量vo2max和超声心动图。肿瘤体积和体积分别为2.1±0.6 g和1685±428(范围256 ~ 3749)mm3。体质量(217±6 vs 218±6 g)、V * O2max(72.1±2.7 vs 70.0±2.8 ml/kg·min);肿瘤形成后,心功能各项指标均无变化,肿瘤体积与vo2max无显著相关性(P > 0.05)。然而,疲劳时间(376±20 vs 297±25 s)、跑步机最终速度(48±1 vs 42±2 m/s)、跑步距离(209±16 vs 152±18 m)和总功(45±3 vs 32±4 m·kg)显著降低。与我们的假设相反,乳腺癌不影响vo2max或心功能,但降低了运动耐量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tumor bearing in untreated breast cancer decreases exercise tolerance without lowering maximal oxygen uptake in rats.

Breast cancer patients' maximal O2 uptake (V̇O2max) values average 60-80% of age-predicted values which is often attributed to adjuvant therapy rather than risk factors, comorbidities, or the tumor and associated factors (e.g., pro-inflammatory cytokines). It is crucial to understand the physiological mechanisms behind exercise intolerance in breast cancer patients to enhance targeted interventions; however, the effect of breast cancer, as an isolated condition on V̇O2max, exercise tolerance, and resting cardiac function has not been investigated. We hypothesized that breast cancer, in the absence of underlying conditions or chemotherapy, would lower V̇O2max, exercise tolerance, and cardiac function in proportion to tumor mass. Female Fischer-344 rats (~6-8 months, n = 8) were acclimatized to treadmill running for 5 days at 25 m/min for 5 min/day. To measure V̇O2max, rats were placed within a plexiglass metabolic chamber connected to CO2 and O2 analyzers. Tests began at 25 m/min and increased (5 m/min) until exhaustion. Cardiac function was determined by echocardiography before rats received a mammary intraductal injection of rat adenocarcinoma cells (MATBIII, 6 × 103 in 50 µl saline). Tumor growth was monitored daily and ~7 days following palpation (~24 days post-injection), V̇O2max and echocardiography measurements were repeated. Tumor mass and volume were 2.1 ± 0.6 g and 1685 ± 428 (range 256-3749) mm3, respectively. Body mass (217 ± 6 vs 218 ± 6 g), V̇O2max (72.1 ± 2.7 vs 70.0 ± 2.8 ml/kg·min; P > 0.05), and all measures of cardiac function were unchanged following tumor formation, with no significant correlation between tumor mass and V̇O2max (P > 0.05). However, time to exhaustion (376 ± 20 vs 297 ± 25 s), final treadmill speed (48 ± 1 vs 42 ± 2 m/s), distance run (209 ± 16 vs 152 ± 18 m), and total work (45 ± 3 vs 32 ± 4 m·kg) were significantly reduced with tumor bearing. Contrary to our hypothesis, breast cancer did not affect V̇O2max or cardiac function, but reduced exercise tolerance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
3.80%
发文量
263
期刊介绍: The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信